Last Updated : May 13, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Opdivo | nivolumab | Gastroesophageal junction or esophageal adenocarcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Darzalex | daratumumab | Light chain (AL) amyloidosis | Reimburse with clinical criteria and/or conditions | Complete | ||
Brukinsa | zanubrutinib | Waldenström’s macroglobulinemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Waymade-Trientine | trientine hydrochloride | Wilson's Disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Ultomiris | ravulizumab | Paroxysmal nocturnal hemoglobinuria | Reimburse with clinical criteria and/or conditions | Complete | ||
Keytruda | pembrolizumab | Classical Hodgkin lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Opsynvi | macitentan and tadalafil | Pulmonary arterial hypertension | Reimburse with clinical criteria and/or conditions | Complete | ||
MAR-Trientine | Trientine Hydrochloride | Wilson's Disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Evenity | romosozumab | Osteoporosis, postmenopausal women | Reimburse with clinical criteria and/or conditions | Complete | ||
Emgality | galcanezumab | Prevention of migraine | Reimburse with clinical criteria and/or conditions | Complete |